Prestige Wealth Management Group LLC Grows Position in AbbVie Inc. $ABBV

Prestige Wealth Management Group LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 165.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,196 shares of the company’s stock after acquiring an additional 7,596 shares during the period. Prestige Wealth Management Group LLC’s holdings in AbbVie were worth $2,824,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the second quarter worth about $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie during the 2nd quarter valued at approximately $36,000. Delos Wealth Advisors LLC bought a new stake in AbbVie in the 2nd quarter worth approximately $39,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of AbbVie during the 3rd quarter worth approximately $41,000. 70.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Evercore cut their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Piper Sandler boosted their target price on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a report on Tuesday, November 4th. Finally, Morgan Stanley lifted their price target on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Announced a $380 million investment to build two active pharmaceutical ingredient (API) plants at its North Chicago campus to support neuroscience and obesity medicines; construction starts spring 2026 and facilities are expected online by 2029, strengthening domestic supply and “Made in U.S.” manufacturing capacity. Article Title
• Positive Sentiment: FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line, all‑oral, fixed‑duration regimen for previously untreated CLL — a label expansion that can meaningfully support oncology revenue growth. Article Title
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and $275 price target, citing upside from operating leverage and under‑appreciated growth potential — a catalyst that can attract buyers. Article Title
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in bipolar I disorder, a data point that supports the product’s real‑world evidence but is unlikely to move near‑term revenue materially. Article Title
• Neutral Sentiment: Analysts have modestly updated fair‑value models (example: a small move to ~$248.29), reflecting mixed views — positive readthroughs on pipeline and immunology assets offset by caution on execution. Article Title
• Negative Sentiment: Investor concerns about competitive pressure in key franchises and execution risk (integration, manufacturing ramp timelines, and maintaining growth after major product lifecycles) are being highlighted in coverage and may be prompting profit‑taking. Article Title

AbbVie Trading Down 0.5%

NYSE:ABBV opened at $228.44 on Wednesday. The company has a market cap of $403.92 billion, a price-to-earnings ratio of 96.80, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a fifty day simple moving average of $224.17 and a 200-day simple moving average of $222.67.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the firm posted $2.16 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s payout ratio is presently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.